# KEYNOTE-942 (NCT03897881)

> An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03897881
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: ModernaTX, Inc.
- Conditions: Melanoma
- Interventions: mRNA-4157; Pembrolizumab
- Enrollment: 267
- Primary outcome: Recurrence-Free Survival (RFS), Assessed Using Radiological Imaging

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Podcasts: 26
- X threads: 25
- YouTube: 20

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=keynote-942-nct03897881

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03897881", "email": "<work email>"}; the inbox owner confirms by the emailed link.